Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Baclofen for Alcohol Withdrawal

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: August 2017

Workgroups: Substance Use Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that there’s not enough high-quality evidence to determine whether baclofen improves symptoms in people with alcohol withdrawal syndrome. The studies included in the review compared baclofen with placebo or another medicine. Researchers concluded that well‐designed double-blind randomized controlled trials with large numbers of participants are needed to test the effectiveness of baclofen.

Read more about this resource

Objectives related to this resource (1)

Reduce the proportion of people who had alcohol use disorder in the past year — SU‑13
Little or no detectable change

Suggested Citation

1.

Liu, J. & Wang, L.N. (2017). Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews, 2017 (8). DOI: 10.1002/14651858.CD008502.pub5.